Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment-Reference-Cited by-同舟云学术

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment

Published:2021-12-12 Issue: Volume: Page:
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharma

Author:

Xu Yan¹,Izumi Raquel²,Nguyen Helen²,Kwan Anna²,Kuo Howard¹,Madere Jeannine²,Slatter J. Greg¹,Podoll Terry¹,Vishwanathan Karthick³^ORCID,Marbury Thomas⁴,Smith William⁵,Preston Richard A.⁶,Sharma Shringi¹,Ware Joseph A.¹

Affiliation:

1. Quantitative Clinical Pharmacology AstraZeneca South San Francisco CA USA

2. Clinical Development AstraZeneca South San Francisco CA USA

3. Clinical Pharmacology and Quantitative Pharmacology Clinical Pharmacology and Safety Sciences AstraZeneca Boston MA USA

4. Orlando Clinical Research Center Orlando FL USA

5. Alliance for Multispecialty Research University of Tennessee Medical Center Knoxville TN USA

6. Division of Clinical Pharmacology Department of Medicine The Peggy and Harold Katz Family Drug Discovery Center University of Miami Clinical and Translational Science Institutes (CTSI) University of Miami Miami FL USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BTK inhibitor–induced defects in human neutrophil effector activity against Aspergillus fumigatus are restored by TNF-α;JCI Insight;2024-05-07

2. Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors;Clinical Pharmacology in Drug Development;2022-08-27